Page last updated: 2024-10-23

benphothiamine and Alzheimer Disease

benphothiamine has been researched along with Alzheimer Disease in 7 studies

benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"The primary clinical outcome was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)."2.94Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. ( Bettendorff, L; Chen, H; Chen, Z; Cirio, R; Flowers, SA; Fonzetti, P; Franchino-Elder, J; Gerber, LM; Gibson, GE; Grandville, T; Habeck, C; Hirsch, JA; Jordan, B; Luchsinger, JA; Schupf, N; Stern, Y; Xu, H, 2020)
" In order to compensate thiamine deficiency, several thiamine precursors with higher bioavailability were developed since the 1950s."2.72Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. ( Bettendorff, L; Sambon, M; Wins, P, 2021)
"The neurodegeneration of Alzheimer's disease (AD) affects not only brain structures associate with cognition early in the progression of the disease, but other areas such as the hypothalamus, a region involved in the control of metabolism and appetite."1.72Benfotiamine protects against hypothalamic dysfunction in a STZ-induced model of neurodegeneration in rats. ( Cardinali, CAEF; Donato, J; Gonçalves, AC; Guerra-Shinohara, EM; Kleinridders, A; Leboucher, A; Lima, GCA; Moraes, RCM; Portari, GV; Torrão, ADS, 2022)
"It is well known that patients with Alzheimer's disease (AD) have imbalances in blood thiamine concentrations and lower activity of thiamine-dependent enzymes."1.56Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration. ( Gonçalves, AC; Moraes, RCM; Portari, GV; Singulani, MP; Torrão, ADS, 2020)
" Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD."1.43Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. ( Bao, W; Chen, Z; Fei, G; Guan, Y; Pan, S; Pan, X; Ren, S; Zhong, C, 2016)
" Here, we tested the effect of benfotiamine, a thiamine derivative with better bioavailability than thiamine, on cognitive impairment and pathology alterations in a mouse model of Alzheimer's disease, the amyloid precursor protein/presenilin-1 transgenic mouse."1.36Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. ( Chen, J; Dong, W; Fei, G; Gong, N; Gu, F; Pan, X; Qin, Y; Sun, X; Xu, TL; Xu, Z; Yu, M; Yu, Z; Zhao, J; Zhao, L; Zhong, C, 2010)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (28.57)24.3611
2020's5 (71.43)2.80

Authors

AuthorsStudies
Bhawal, R1
Fu, Q1
Anderson, ET1
Gibson, GE2
Zhang, S1
Moraes, RCM2
Lima, GCA1
Cardinali, CAEF1
Gonçalves, AC2
Portari, GV2
Guerra-Shinohara, EM1
Leboucher, A1
Donato, J1
Kleinridders, A1
Torrão, ADS2
Singulani, MP1
Luchsinger, JA1
Cirio, R1
Chen, H1
Franchino-Elder, J1
Hirsch, JA1
Bettendorff, L2
Chen, Z2
Flowers, SA1
Gerber, LM1
Grandville, T1
Schupf, N1
Xu, H1
Stern, Y1
Habeck, C1
Jordan, B1
Fonzetti, P1
Sambon, M1
Wins, P1
Pan, X2
Fei, G2
Pan, S1
Bao, W1
Ren, S1
Guan, Y1
Zhong, C2
Gong, N1
Zhao, J1
Yu, Z1
Gu, F1
Chen, J1
Sun, X1
Zhao, L1
Yu, M1
Xu, Z1
Dong, W1
Qin, Y1
Xu, TL1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Benfotiamine in Alzheimer's Disease: A Pilot Study[NCT02292238]Phase 271 participants (Actual)Interventional2015-02-15Completed
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Safety and Efficacy of Qualia Mind on Cognition in a Healthy Population[NCT04389723]60 participants (Actual)Interventional2020-05-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in ADAS-Cog Score

"The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials and is considered to be the gold standard for assessing antidementia treatments. The ADAS-Cog range from 0 to 70, where higher scores indicate greater cognitive dysfunction." (NCT02292238)
Timeframe: Baseline, 1 year

Interventionscore on a scale (Mean)
Benfotiamine1.39
Placebo3.26

Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score

Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) is a caregiver-based Activities of Daily Living (ADL) scale composed of 23 items developed for use in dementia clinical studies. It was designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, as well as making judgments and decisions. The range for the total ADCS-ADL score is 0 to 78. Higher scores equate with higher functioning. (NCT02292238)
Timeframe: Baseline, 1 year

Interventionscore on a scale (Mean)
Benfotiamine-1.931
Placebo-3.16129

Change From Baseline in Brain Glucose Utilization

The AAL (Automatic Anatomical Labeling) atlas provides the taxonomy for 116 regions of interest, 90 of which capture non-cerebellar cortical regions. Signal averages from 9 cerebellar regions from each hemisphere were further averaged into one composite cerebellar region for each hemisphere, 'Cerebellum_L' and 'Cerebellum_R', which were comprised of the respective laterality averages of the regions: 'Cerebellum_Crus1 ' 'Cerebellum_Crus2 'Cerebellum_3' 'Cerebellum_4_5' 'Cerebellum_6' 'Cerebellum_7b' 'Cerebellum_8' 'Cerebellum_9' 'Cerebellum_10 '. Subsequently, these two composite regions are further combined with the bilateral paracentral lobules to provide one final composite for reference scaling. Concretely, the values from 'Cerebellum_L', 'Cerebellum_R', 'Paracentral_Lobule_L', and 'Paracentra_Lobule_R' were averaged. This final composite will serve as the denominator for the scaling operation of any ROI value prior to group-level analysis. (NCT02292238)
Timeframe: Baseline, 1 year

Interventionratio (Mean)
Benfotiamine-0.02
Placebo-0.01

Change From Baseline in Buschke Selective Reminding Test (SRT) Score

The SRT is a standard diagnostic tool in the assessment of verbal memory. The Buschke SRT immediate total scores are compared between treated (benfotiamine) and control (placebo) groups. The immediate total score is the sum of correct responses over the 6 learning trials with scores ranging from 0 to 72. A score of 0 means severe impairment in memory. A score of 72 means there is no impairment in memory. For the purpose of determining effect over several trials between groups, the fractional change from the baseline of each group is compared. (NCT02292238)
Timeframe: Baseline, 1 year

Interventionscore on a scale (Mean)
Benfotiamine0.86
Placebo-1.12

Change From Baseline in Clinical Dementia Rating (CDR) Score

The CDR was developed primarily for use in persons with dementia of the Alzheimer type (the equivalent of probable Alzheimer's Disease) and can also be used to stage dementia in other illnesses as well. The scores for the multiple items are summarized in one score. The CDR examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change. (NCT02292238)
Timeframe: Baseline, 1 year

Interventionscore on a scale (Mean)
Benfotiamine0.05
Placebo0.22

Change From Baseline in Neuropsychiatric Inventory (NPI) Score

The NPI assesses a wide range of behaviors encountered in dementia patients to provide a means of distinguishing frequency and severity of behavioral changes. Ten behavioral and two neuro-vegetative domains are evaluated through an interview with the caregiver. The total score ranges from 0 to 144. Higher scores suggest greater psychiatric impairment. (NCT02292238)
Timeframe: Baseline, 1 year

Interventionscore on a scale (Mean)
Benfotiamine6.69
Placebo9.23

Reviews

1 review available for benphothiamine and Alzheimer Disease

ArticleYear
Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine.
    International journal of molecular sciences, 2021, May-21, Volume: 22, Issue:11

    Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Humans; Neuroprotection; Neuroprotective Agent

2021

Trials

1 trial available for benphothiamine and Alzheimer Disease

ArticleYear
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
    Journal of Alzheimer's disease : JAD, 2020, Volume: 78, Issue:3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Apolipoprotein E4; Brain; Cognitive D

2020

Other Studies

5 other studies available for benphothiamine and Alzheimer Disease

ArticleYear
Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.
    International journal of molecular sciences, 2021, Dec-07, Volume: 22, Issue:24

    Topics: Alzheimer Disease; Biomarkers; Case-Control Studies; Chromatography, Liquid; Humans; Lipids; Mass Sp

2021
Benfotiamine protects against hypothalamic dysfunction in a STZ-induced model of neurodegeneration in rats.
    Life sciences, 2022, Oct-01, Volume: 306

    Topics: Alzheimer Disease; Animals; Disease Models, Animal; Rats; Streptozocin; Thiamine

2022
Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration.
    Experimental gerontology, 2020, Volume: 141

    Topics: Alzheimer Disease; Animals; Brain; Cognition; Humans; Rats; Thiamine; Thiamine Pyrophosphate

2020
Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.
    Neuroscience bulletin, 2016, Volume: 32, Issue:6

    Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Chromatograph

2016
Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
    Brain : a journal of neurology, 2010, Volume: 133, Issue:Pt 5

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Cognition; Cognition Diso

2010